199 related articles for article (PubMed ID: 23897281)
1. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines.
Erdoğ A; Putra Limasale YD; Keskin D; Tezcaner A; Banerjee S
J Pharm Sci; 2013 Oct; 102(10):3666-77. PubMed ID: 23897281
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.
Deniz A; Sade A; Severcan F; Keskin D; Tezcaner A; Banerjee S
Biosci Rep; 2010 Jun; 30(5):365-73. PubMed ID: 19900165
[TBL] [Abstract][Full Text] [Related]
3. In-vitro characterisation of a novel celecoxib microbead formulation for the treatment and prevention of colorectal cancer.
McDonald BF; Quinn AM; Devers T; Cullen A; Coulter IS; Marison IW; Loughran ST
J Pharm Pharmacol; 2015 May; 67(5):685-95. PubMed ID: 25650335
[TBL] [Abstract][Full Text] [Related]
4. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
5. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells.
Limasale YD; Tezcaner A; Özen C; Keskin D; Banerjee S
Int J Pharm; 2015 Feb; 479(2):364-73. PubMed ID: 25595386
[TBL] [Abstract][Full Text] [Related]
7. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil.
Al Asmari AK; Ullah Z; Tariq M; Fatani A
Drug Des Devel Ther; 2016; 10():205-15. PubMed ID: 26834457
[TBL] [Abstract][Full Text] [Related]
8. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
9. Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model.
Dong J; Jiang D; Wang Z; Wu G; Miao L; Huang L
Int J Pharm; 2013 Jan; 441(1-2):285-90. PubMed ID: 23194887
[TBL] [Abstract][Full Text] [Related]
10. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression.
Sade A; Tunçay S; Cimen I; Severcan F; Banerjee S
Biosci Rep; 2012 Feb; 32(1):35-44. PubMed ID: 21401528
[TBL] [Abstract][Full Text] [Related]
12. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.
Jain SK; Gupta Y; Jain A; Bhola M
Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522
[TBL] [Abstract][Full Text] [Related]
13. Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy.
Corvo ML; Mendo AS; Figueiredo S; Gaspar R; Larguinho M; Guedes da Silva MF; Baptista PV; Fernandes AR
Pharm Res; 2016 Jun; 33(6):1351-8. PubMed ID: 27033349
[TBL] [Abstract][Full Text] [Related]
14. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
15. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.
Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB
Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941
[TBL] [Abstract][Full Text] [Related]
16. pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.
Yang MM; Wilson WR; Wu Z
Int J Pharm; 2017 Jan; 516(1-2):323-333. PubMed ID: 27871834
[TBL] [Abstract][Full Text] [Related]
17. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
18. Liposomal gels for site-specific, sustained delivery of celecoxib: in vitro and in vivo evaluation.
Fetih G; Fathalla D; El-Badry M
Drug Dev Res; 2014 Jun; 75(4):257-66. PubMed ID: 24939834
[TBL] [Abstract][Full Text] [Related]
19. Concentration-dependent differing actions of the nonsteroidal anti-inflammatory drug, celecoxib, in distearoyl phosphatidylcholine multilamellar vesicles.
Sade A; Banerjee S; Severcan F
J Liposome Res; 2010 Jun; 20(2):168-77. PubMed ID: 19848445
[TBL] [Abstract][Full Text] [Related]
20. Cell-penetrating Peptide-coated Liposomes for Drug Delivery Across the Blood-Brain Barrier.
Yuan BO; Zhao Y; Dong S; Sun Y; Hao F; Xie J; Teng L; Lee RJ; Fu Y; Bi YE
Anticancer Res; 2019 Jan; 39(1):237-243. PubMed ID: 30591464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
